Showing 1071-1080 of 6947 results for "".
Bryhali, Xepi Launches; Epionce's New Facility
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-bryhali-xepi-launches-epionce-s-new-facility/18213/Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square fooLift Off: Non-Invasive Skin Tightening
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/lift-off-non-invasive-skin-tightening/18223/Arisa Ortiz, MD says that minimally invasive devices won't approach surgical results, but patients can get significant improvement. She discusses patient selection, expectations, and outcomes with host Joel L. Cohen, MD.BrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-brightguard-covers-nyc-galderma-uncovers-rosacea-burden-dermira-s-qbrexza-approved/18288/BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify theNew eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-erelevance-services-cosmetic-bootcamp-updates-leo-aid-partnership/18291/eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to boardValeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-s-siliq-cleared-amspa-survey-new-skin-cancer-imaging/18527/The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitoAdvanced Systemic Therapeutics
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-systemic-therapeutics/18755/By Seemal R. Desai, MD and Neal Bhatia, MD, FAADFrom updates in infectious disease to hormonal therapies, and off-label uses of biologics, the key to successful treatment is matching mechanisms to disease states. Dr. Bhatia explains.A Layered Approach to Contouring and Refilling
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-layered-approach-to-contouring-and-refilling/18611/Having moved well beyond the days when fillers could only fill in fine lines, aesthetic physicians can now help to rebuild contour, re-establish balance, and smooth out lines, says Vic Narurkar, MD, FAAD. He discusses his approach to contouring and refilling.Improving Patient Interactions
https://practicaldermatology.com/topics/practice-management/improving-patient-interactions/18805/From treating hospitalized patients, to delivering bad news, to helping patients manage chronic conditions, and even dealing with difficult patients, this episode of Derm Insider focuses on improving patient care and the doctor/patient relationship. Joanna L. Harp, MD, Kanade Shinkai, MD, PhD, KristConsiderations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodEnstilar Approved; New Data for Otezla, Duac
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enstilar-approved-new-data-for-otezla-duac/18687/LEO Pharma's Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% has been FDA-approved for plaque psoriasis. New data presented at EADV on Stiefel's Duac, Celgene's Otezla, and Boehringer Ingelheim's investigational biologic compound BI 655066. Plus, Galderma's OTC Excipial l